{
    "root": "32be8920-84d2-31bc-e063-6394a90ab438",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Tadalafil",
    "value": "20250414",
    "ingredients": [
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 100000 MW)",
            "code": "BMJ7J4127K"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "FD&C YELLOW NO. 5",
            "code": "I753WB2F1M"
        },
        {
            "name": "ALUMINUM OXIDE",
            "code": "LMI26O6933"
        },
        {
            "name": "TADALAFIL",
            "code": "742SXX0ICT"
        }
    ],
    "indications": "tadalafil phosphodiesterase 5 ( pde5 ) inhibitor indicated treatment : erectile dysfunction ( ed ) ( 1.1 ) signs symptoms benign prostatic hyperplasia ( bph ) ( 1.2 ) ed signs symptoms bph ( ed/bph ) ( 1.3 ) tadalafil used finasteride initiate bph treatment , recommended 26 weeks ( 1.4 ) .",
    "contraindications": "split tadalafil tablets ; entire dose taken .",
    "warningsAndPrecautions": null,
    "adverseReactions": "tadalafil patients using form organic nitrate contraindicated . tadalafil shown potentiate hypotensive effect nitrates ( 4.1 ) . history known serious hypersensitivity reaction tadalafil adcirca ® ( 4.2 ) . guanylate cyclase ( gc ) stimulators , riociguat ( 4.3 ) .",
    "indications_original": "Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: erectile dysfunction (ED) ( 1.1 ) the signs and symptoms of benign prostatic hyperplasia (BPH) ( 1.2 ) ED and the signs and symptoms of BPH (ED/BPH) ( 1.3 ) If tadalafil is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks ( 1.4 ).",
    "contraindications_original": "Do not split Tadalafil tablets; entire dose should be taken.",
    "adverseReactions_original": "Administration of tadalafil to patients using any form of organic nitrate is contraindicated. Tadalafil was shown to potentiate the hypotensive effect of nitrates ( 4.1 ). History of known serious hypersensitivity reaction to Tadalafil or ADCIRCA ® ( 4.2 ). Administration with guanylate cyclase (GC) stimulators, such as riociguat ( 4.3 )."
}